Custom immune cells take on advanced colorectal cancer in early trial

NCT ID NCT07504523

Recruiting now Disease control Sponsor: Ying Yuan, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a personalized treatment called iNeo-Vac-T01 for people with advanced colorectal cancer. The therapy uses a patient's own immune cells, which are trained in a lab to recognize and attack unique markers on their tumor. The study will enroll 20 participants to see if this approach is safe and feasible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iNeo-Vac-T01 (personalized T-cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced colorectal cancer who have run out of standard options.
What could go wrong: This is a very early, small Phase 1 trial with only 20 people. It is primarily testing safety and feasibility, so it may not show strong anti-cancer effects. There are also risks of side effects from the cell infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER (CRC)

Contacts and locations

Locations

2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
RECRUITING

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.